دورية أكاديمية
أعرض في EDS

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.

التفاصيل البيبلوغرافية
العنوان: Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
المؤلفون: Lesokhin AM; Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York City, NY, USA. lesokhia@mskcc.org., Tomasson MH; Department of Internal Medicine, University of Iowa, Iowa City, IA, USA., Arnulf B; Hôpital Saint-Louis, Paris, France., Bahlis NJ; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada., Miles Prince H; Epworth Healthcare and University of Melbourne, Melbourne, Victoria, Australia., Niesvizky R; Weill Cornell Medical College/New York Presbyterian Hospital, New York City, NY, USA., Rodrίguez-Otero P; Clinica Universidad de Navarra, Madrid, Spain., Martinez-Lopez J; Hospital Universitario 12 de Octubre, Madrid, Spain., Koehne G; Miami Cancer Institute, Miami, FL, USA., Touzeau C; University Hospital of Nantes, Nantes, France., Jethava Y; Indiana Blood & Marrow Transplant, Indianapolis, IN, USA., Quach H; University of Melbourne, St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia., Depaus J; Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium., Yokoyama H; Tohoku University Graduate School of Medicine, Sendai, Japan., Gabayan AE; Beverly Hills Cancer Center, Beverly Hills, CA, USA., Stevens DA; Norton Cancer Center, Louisville, KY, USA., Nooka AK; Winship Cancer Institute, Atlanta, GA, USA., Manier S; Lille University Hospital and INSERM UMR-S1277, Lille, France., Raje N; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Iida S; Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan., Raab MS; Heidelberg Myeloma Center, Department of Hematology/Oncology, Heidelberg University Hospital, Heidelberg, Germany., Searle E; The Christie Hospital, The University of Manchester, Manchester, UK., Leip E; Pfizer Inc, Cambridge, MA, USA., Sullivan ST; Pfizer Inc, Cambridge, MA, USA., Conte U; Pfizer Inc, New York, NY, USA., Elmeliegy M; Pfizer Inc, San Diego, CA, USA., Czibere A; Pfizer Inc, New York, NY, USA., Viqueira A; Pfizer SLU, Madrid, Spain., Mohty M; Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France.
المصدر: Nature medicine [Nat Med] 2023 Sep; Vol. 29 (9), pp. 2259-2267. Date of Electronic Publication: 2023 Aug 15.
نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
أسماء مطبوعة: Publication: New York Ny : Nature Publishing Company
Original Publication: New York, NY : Nature Pub. Co., [1995-
مواضيع طبية MeSH: Multiple Myeloma*/drug therapy, Humans ; B-Cell Maturation Antigen ; Progression-Free Survival ; Remission Induction
مستخلص: Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. After six cycles, persistent responders switched to biweekly dosing. Results from cohort A, which enrolled patients without prior BCMA-directed therapy (n = 123) are reported. The primary endpoint of confirmed objective response rate (ORR) by blinded independent central review was met with an ORR of 61.0% (75/123); 35.0% ≥complete response. Fifty responders switched to biweekly dosing, and 40 (80.0%) improved or maintained their response for ≥6 months. With a median follow-up of 14.7 months, median duration of response, progression-free survival and overall survival (secondary endpoints) have not been reached. Fifteen-month rates were 71.5%, 50.9% and 56.7%, respectively. Common adverse events (any grade; grade 3-4) included infections (69.9%, 39.8%), cytokine release syndrome (57.7%, 0%), anemia (48.8%, 37.4%), and neutropenia (48.8%, 48.8%). With biweekly dosing, grade 3-4 adverse events decreased from 58.6% to 46.6%. Elranatamab induced deep and durable responses with a manageable safety profile. Switching to biweekly dosing may improve long-term safety without compromising efficacy. ClinicalTrials.gov identifier: NCT04649359 .
(© 2023. The Author(s).)
References: Mateos, M. V. et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia 36, 1371–1376 (2022). (PMID: 10.1038/s41375-022-01531-2353322789061296)
Rodriguez-Otero, P. & San-Miguel, J. F. Cellular therapy for multiple myeloma: what’s now and what’s next. Hematol. Am. Soc. Hematol. Educ. Program 2022, 180–189 (2022). (PMID: 10.1182/hematology.2022000396)
Shah, N., Chari, A., Scott, E., Mezzi, K. & Usmani, S. Z. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985–1005 (2020). (PMID: 10.1038/s41375-020-0734-z320550007214244)
Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495–505 (2022). (PMID: 10.1056/NEJMoa220347835661166)
Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021). (PMID: 10.1056/NEJMoa202485033626253)
Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398, 314–324 (2021). (PMID: 10.1016/S0140-6736(21)00933-834175021)
Celgene Corporation, a Bristol-Myers Squibb Company. ABECMA ® (idecabtagene vicleucel) prescribing information. https://www.fda.gov/media/147055/download (2021).
Janssen Biotech, Inc. CARVYKTI ® (ciltacabtagene autoleucel) prescribing information. https://www.fda.gov/media/156560/download (2022).
Janssen Biotech, Inc. TECVAYLI ™ (teclistamab-cqyv) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761291s000lbl.pdf (2022).
Panowski, S. H. et al. Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma. Mol. Cancer Ther. 18, 2008–2020 (2019). (PMID: 10.1158/1535-7163.MCT-19-000731434693)
Nizar, J. B. et al. Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). J. Clin. Oncol. 39, 8006 (2021). (PMID: 10.1200/JCO.2021.39.15_suppl.8006)
Sebag, M. et al. Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from MagnetisMM-1. Blood 138, 895 (2021). (PMID: 10.1182/blood-2021-150519)
Andrzej, J. J. et al. Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: updated results from MagnetisMM-1. J. Clin. Oncol. 40, 8014 (2022). (PMID: 10.1200/JCO.2022.40.16_suppl.8014)
Raje, N. et al. Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma. Blood 140, 388–390 (2022). (PMID: 10.1182/blood-2022-166494)
Lesokhin, A. M. et al. Initial safety results for MagnetisMM-3: a phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). J. Clin. Oncol. 40, 8006 (2022). (PMID: 10.1200/JCO.2022.40.16_suppl.8006)
Lesokhin, A. et al. Magnetismm-3: an open-label, multicenter, non-randomized phase 2 study of elranatamab (PF-06863135) in patients with relapsed or refractory multiple myeloma. Blood 138, 1674 (2021). (PMID: 10.1182/blood-2021-152984)
Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328–e346 (2016). (PMID: 10.1016/S1470-2045(16)30206-627511158)
Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625–638 (2019). (PMID: 10.1016/j.bbmt.2018.12.75830592986)
Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207–221 (2020). (PMID: 10.1016/S1470-2045(19)30788-031859245)
Blade, J. et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 12, 45 (2022). (PMID: 10.1038/s41408-022-00643-3353146758938478)
Palumbo, A. et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J. Clin. Oncol. 33, 2863–2869 (2015). (PMID: 10.1200/JCO.2015.61.2267262402244846284)
Gill, S. K. et al. I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients. Blood Cancer J. 12, 138 (2022). (PMID: 10.1038/s41408-022-00733-2361510909508328)
Lonial, S. et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer 127, 4198–4212 (2021). (PMID: 10.1002/cncr.3380934314018)
Donk de van, N. W. C. J. et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). J. Clin. Oncol. 41, 8011 (2023). (PMID: 10.1200/JCO.2023.41.16_suppl.8011)
Martin, T. et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41, 1265–1274 (2023). (PMID: 10.1200/JCO.22.0084235658469)
Chari, A. et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl. J. Med. 387, 2232–2244 (2022). (PMID: 10.1056/NEJMoa220459136507686)
GlaxoSmithKline, Ltd. BLENREP (belantamab mafodotin-blmf) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf (2020).
Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609–2617 (2003). (PMID: 10.1056/NEJMoa03028812826635)
Rajkumar, S. V. Thalidomide in the treatment of multiple myeloma. Expert Rev. Anticancer Ther. 1, 20–28 (2001). (PMID: 10.1586/14737140.1.1.2012113124)
Sim, B. Z. et al. Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood Cancer J. 13, 34 (2023). (PMID: 10.1038/s41408-023-00808-8368945399998258)
Mazahreh, F. et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 7, 3069–3074 (2023). (PMID: 10.1182/bloodadvances.20220094353685775510331406)
Kambhampati, S. et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 6, 2045–2054 (2022). (PMID: 10.1182/bloodadvances.2020004079345434009006279)
Mikkilineni, L. et al. Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. Blood Adv. 5, 5312–5322 (2021). (PMID: 10.1182/bloodadvances.2021004896346197689153053)
Mohan, M. et al. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Adv. 6, 2466–2470 (2022). (PMID: 10.1182/bloodadvances.2021006178349333449043928)
D’Souza, A. et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. J. Clin. Oncol. 40, 3576–3586 (2022). (PMID: 10.1200/JCO.22.01504360295279622641)
Raje, N. S. et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 9, e143–e161 (2022). (PMID: 10.1016/S2352-3026(21)00283-035114152)
Ludwig, H. et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 24, e255–e269 (2023). (PMID: 10.1016/S1470-2045(23)00159-637269857)
Terpos, E. et al. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). Leukemia 37, 1175–1185 (2023). (PMID: 10.1038/s41375-023-01920-13714266110157596)
Raje, N. A. et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving 1 bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 13, 116 (2023). (PMID: 10.1038/s41408-023-00879-73752808810394080)
معلومات مُعتمدة: P30 CA008748 United States CA NCI NIH HHS; P30 CA086862 United States CA NCI NIH HHS
سلسلة جزيئية: ClinicalTrials.gov NCT04649359
المشرفين على المادة: 0 (B-Cell Maturation Antigen)
تواريخ الأحداث: Date Created: 20230815 Date Completed: 20230918 Latest Revision: 20231122
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10504075
DOI: 10.1038/s41591-023-02528-9
PMID: 37582952
قاعدة البيانات: MEDLINE
الوصف
تدمد:1546-170X
DOI:10.1038/s41591-023-02528-9